Asset Details
Do you wish to reserve the book?
A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval
Do you wish to request the book?
A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval
2025
Overview
Rosuvastatin can block human ether-a-go-go related gene (hERG) currents and prolong the corrected QT (QTc) interval, but this effect has not been confirmed in the population. This study compared the changes of QTc interval between populations receiving atorvastatin and rosuvastatin, explained the effect of rosuvastatin on QTc interval, and the correlation between rosuvastatin and QT prolongation. The QTc interval decreased by 0.83 ms from baseline in atorvastatin group and increased by 6.57 ms in rosuvastatin group. More patients in the rosuvastatin group had an increased QTc interval (62.7% vs. 46.6%, p< 0.001). Rosuvastatin increased the risk of newly emerged QT prolongation by 42% (95% CI 1.10–1.85,
p
= 0.008). But there was no correlation between rosuvastatin and severe QT prolongation (RR 1.23, 95% CI 0.74–2.06,
p
= 0.426). In conclusion, rosuvastatin exhibits a modest adverse effect on the QTc interval. Rosuvastatin monotherapy does not appear to increase the risk of arrhythmia. But this study did not assess the usage of rosuvastatin with other QT-prolonging drugs, the potential for an additive effect should be considered when combining rosuvastatin with other QT-prolonging drugs.
Trial registration: ChiCTR2400092701 (21/11/2024)
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Atorvastatin - administration & dosage
/ Atorvastatin - adverse effects
/ Atorvastatin - therapeutic use
/ Electrocardiography - drug effects
/ Female
/ Humanities and Social Sciences
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Long QT Syndrome - chemically induced
/ Male
/ Rosuvastatin Calcium - administration & dosage
/ Rosuvastatin Calcium - adverse effects
/ Rosuvastatin Calcium - therapeutic use
/ Science
/ Statins
